FEB 19, 2018 10:28 AM PST

Blood Pressure Drug Prevents Onset of Type 1 Diabetes

WRITTEN BY: Kara Marker

There’s a new way to prevent the onset of type 1 diabetes with an old drug. Methyldopa has been treating high blood pressure in pregnant women and children for more than 50 years, but in a decade-long study, researchers from the University of Colorado Anschutz Medical Campus introduce a new way to put this drug to good use.

Human beta cells and insulin granules. Credit: Wikimedia user Wikimaji

"We can now predict with almost 100 percent accuracy who is likely to get type 1 diabetes," explained Aaron Michels, PhD, from the University of Colorado. "The goal with this drug is to delay or prevent the onset of the disease among those at risk.”

In studies with animal models of type 1 diabetes and a clinical trial with 20 people with the disease, Michels and others successfully showed how methyldopa can prevent onset of type 1 diabetes in 60 percent of people at risk for the disease. This percentage of people have a specific molecule, DQ8. The presence of DQ8 significantly increases an individual’s likelihood of developing type 1 diabetes. The adaption of methyldopa to type 1 diabetes marks the first personalized treatment for the disease.

With its connection to the risk of developing type 1 diabetes, researchers theorized that by blocking DQ8, they could prevent the onset of the disease. They used a supercomputer to assess thousands of drugs for their ability to bind DQ8.

"All drugs have off-target effects,” Michels explained. "We took every FDA-approved small molecule drug and analyzed HLA-DQ8 binding through a supercomputer. We searched a thousand orientations for each drug to identify those that would fit within the DQ8 molecule binding groove."

Methyldopa blocks DQ8 but also leaves the immune system alone, making it a particularly good candidate for preventing type 1 diabetes. As an autoimmune disease where the immune system mistakenly attacks beta cells, which produce insulin, many existing treatments for type 1 diabetes involve suppressing the immune system. While those drugs may reduce the immune attack on beta cells, they also leave the individual taking the drug vulnerable to infections.

In addition to preventing and treating type 1 diabetes, methyldopa is also potentially applicable to other autoimmune diseases connected to DQ8. For example, rheumatoid arthritis, celiac disease, multiple sclerosis, and lupus could all be impacted by drugs that block DQ8.

Going forward, Michels and his team will be continuing their study of methyldopa in the context of type 1 diabetes with a larger clinical trial to begin in the spring.

The present study was published in the journal Journal of Clinical Investigation.

Sources: JDRF, University of Colorado Anschutz Medical Campus

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 07, 2020
Cancer
Immune-Related Genes as Prognostic Biomarkers
AUG 07, 2020
Immune-Related Genes as Prognostic Biomarkers
Cancer is one of the most persistent and hardy diseases. Cancers often develop the ability to suppress the immune system ...
OCT 02, 2020
Clinical & Molecular DX
Detecting Dystonia in the Blink of an AI
OCT 02, 2020
Detecting Dystonia in the Blink of an AI
A team of scientists have created a diagnostic tool, powered by artificial intelligence (AI), that can pick up on the su ...
OCT 03, 2020
Clinical & Molecular DX
Test Diagnoses Dementia While You Sleep by Estimating Your Brain Age
OCT 03, 2020
Test Diagnoses Dementia While You Sleep by Estimating Your Brain Age
Researchers at Harvard have discovered a novel diagnostic marker of dementia for identifying undiagnosed patients or tho ...
OCT 13, 2020
Clinical & Molecular DX
Test for Diabetes Checks If the Liver Is Responding
OCT 13, 2020
Test for Diabetes Checks If the Liver Is Responding
Glucagon is a hormone that prevents blood glucose levels from dropping too low by stimulating the liver to convert store ...
NOV 10, 2020
Clinical & Molecular DX
No More False-Negatives: An Ultrasensitive COVID Test
NOV 10, 2020
No More False-Negatives: An Ultrasensitive COVID Test
A team of researchers has improved upon the current diagnostic methodology for COVID-19, making it significantly more ac ...
NOV 24, 2020
Clinical & Molecular DX
Young Inventor Creates Award-winning At-home Cancer Diagnostic
NOV 24, 2020
Young Inventor Creates Award-winning At-home Cancer Diagnostic
Getting a breast cancer diagnosis often means having to endure multiple tests, including some painful and invasive proce ...
Loading Comments...